Detalles de la búsqueda
1.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Ann Oncol
; 31(8): 1001-1010, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416251
Resultados
1 -
1
de 1
1
Próxima >
>>